1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Year: 2023
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: J.C-H. Yang, M. Wang, C-H. Chiu, P-C. Hsu, P. Mitchell, C.L. Chang, T.M. Kim, T. John, L. Greillier, L. Bazhenova, E. Carcereny, A.I. Spira, B. Shim, K.H. Lee, M. Cobo Dols, F. Ghiringhelli, C.W. Yip, J. Xiong, P.A. Jänne, C. Zhou
Institutions: National Taiwan University Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Taipei Veterans General Hospital, Chang Gung Memorial Hospital, Taoyuan Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, Austin Hospital, Olivia Newton-John Cancer Wellness & Research Centre, Wan Fang Hospital, Seoul National University, Seoul National University Hospital, Peter MacCallum Cancer Centre, Hôpital de la Timone, Moores Cancer Center, Institut Català d'Oncologia, Virginia Cancer Specialists, The Catholic University of Korea St. Vincent's Hospital, Chungbuk National University, Chungbuk National University Hospital, Hospital Regional Universitario de Málaga, Centre Georges François Leclerc, Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China), Dana-Farber Cancer Institute, Tongji University, Shanghai Pulmonary Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: AstraZeneca, Sanofi, Foundation Medicine
OpenAlex ID: W4387825596